Sphingosylphosphorylcholine Induces Thrombospondin-1 Secretion in MCF10A Cells via ERK2.
10.4062/biomolther.2016.228
- Author:
June Hee KANG
1
;
Hyun Ji KIM
;
Mi Kyung PARK
;
Chang Hoon LEE
Author Information
1. College of Pharmacy, Dongguk University, Seoul 10326, Republic of Korea. uatheone@dongguk.edu
- Publication Type:Original Article
- Keywords:
Sphingosylphosphorylcholine;
Thrombospondin-1;
Epithelial mesenchymal transition;
ERK2
- MeSH:
Apoptosis;
Breast Neoplasms;
Cadherins;
Cell Movement;
Cell Proliferation;
Epithelial-Mesenchymal Transition;
Gene Silencing;
Humans;
Inflammation;
Neoplasm Metastasis;
Phenotype;
Phospholipids;
Phosphotransferases;
Receptors, Cell Surface;
Recurrence;
RNA, Small Interfering;
Thrombospondin 1;
Vimentin
- From:Biomolecules & Therapeutics
2017;25(6):625-633
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sphingosylphosphorylcholine (SPC) is one of the bioactive phospholipids that has many cellular functions such as cell migration, adhesion, proliferation, angiogenesis, and Ca²⁺ signaling. Recent studies have reported that SPC induces invasion of breast cancer cells via matrix metalloproteinase-3 (MMP-3) secretion leading to WNT activation. Thrombospondin-1 (TSP-1) is a matricellular and calcium-binding protein that binds to a wide variety of integrin and non-integrin cell surface receptors. It regulates cell proliferation, migration, and apoptosis in inflammation, angiogenesis and neoplasia. TSP-1 promotes aggressive phenotype via epithelial mesenchymal transition (EMT). The relationship between SPC and TSP-1 is unclear. We found SPC induced EMT leading to mesenchymal morphology, decrease of E-cadherin expression and increases of N-cadherin and vimentin. SPC induced secretion of thrombospondin-1 (TSP-1) during SPC-induced EMT of various breast cancer cells. Gene silencing of TSP-1 suppressed SPC-induced EMT as well as migration and invasion of MCF10A cells. An extracellular signal-regulated kinase inhibitor, PD98059, significantly suppressed the secretion of TSP-1, expressions of N-cadherin and vimentin, and decrease of E-cadherin in MCF10A cells. ERK2 siRNA suppressed TSP-1 secretion and EMT. From online PROGgene V2, relapse free survival is low in patients having high TSP-1 expressed breast cancer. Taken together, we found that SPC induced EMT and TSP-1 secretion via ERK2 signaling pathway. These results suggests that SPC-induced TSP-1 might be a new target for suppression of metastasis of breast cancer cells.
